CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a biotechnology company pioneering biologically active cellular therapies to treat vascular and other serious diseases, today announced new preclinical data for the Company’s minimally invasive cell therapy, PVS-10200. Results from the preclinical study found that treatment with PVS-10200 (tissue engineered allogeneic endothelial cells) following an intervention for peripheral arterial disease (PAD) resulted in a statistically significant increased lumen area, reduced intimal area, and decreased occlusion compared to control. These data were presented in an oral presentation today at EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions in Barcelona, Spain.
